Emerging in the arena of obesity therapy, retatrutide is a different approach. Different from many current medications, retatrutide functions as a double agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) binding sites. This simultaneous stimulation fosters multiple advanta